Redmile Group
Redmile Group is a healthcare-focused investment manager active across public and private markets.
Website or institutional source
- Fundamental equity long/short manager
- Equity Long/Short & Fundamental Hedge Funds
- Tier III
Overview
Redmile Group is a healthcare-focused investment manager active across public and private markets. Its work spans biotechnology, medical devices, diagnostics, healthcare services, and other businesses influenced by scientific and clinical innovation.
The firm’s crossover model allows research to follow companies from private financing through public ownership. This can deepen knowledge of management, products, and competitive positioning, while also requiring careful governance around valuation and liquidity. Within The Economy Wiki, the institution is connected to the Equity Long/Short & Fundamental Hedge Funds category.
Firm facts
| Institution | Redmile Group |
| Type | Fundamental equity long/short manager |
| Headquarters | San Francisco, United States |
| Founded | 2007 |
| Primary ranking focus | Equity Long/Short & Fundamental Hedge Funds |
| Highest 2026 tier | Tier III |
Activities and investment capabilities
Redmile Group is active in company research, security selection, short analysis and equity portfolio construction. Its category-specific capabilities are summarized below.
Core capability
company research, security selection, short analysis and equity portfolio construction
Institutional relevance
Capabilities are assessed for professional investors, investment organizations, counterparties or hedge-fund operating teams.
Risk and execution
The profile considers research quality, implementation, governance, resilience and category-specific operating requirements.
Strategy and market coverage
Strategy and workflow coverage
company research, security selection, short analysis and equity portfolio construction
Institutional context
Coverage reflects the institution’s role in hedge-fund investment, data, trading, financing, risk or operational workflows.
Market position
Redmile fits Tier III because it has an established healthcare investment identity and meaningful public-equity relevance. Its smaller scale and sector concentration support specialist placement.
Redmile Group is assessed within the Equity Long/Short & Fundamental Hedge Funds framework. For wider market context, see Private Equity Technology Due Diligence in the AI Era.
Competitive context
Redmile Group is recognized Tier III in Top 30 Equity Long/Short & Fundamental Hedge Funds 2026. The rankings compare institutions by category relevance, investment or operating capability, research depth, risk and execution quality, institutional credibility and current activity. Comparable links support navigation and do not imply identical mandates, products or counterparties.
Leadership and governance
Leadership, investment-committee composition, product ownership and operating resources may change over time. Current information should be confirmed through the institution’s website or public institutional source.
| Leadership area | Current source |
|---|---|
| Leadership and governance | Current institutional information |
Corporate and public information
This profile refers to Redmile Group as the public-facing institution or platform. Individual funds, advisers, broker-dealers, banks, administrators, data businesses and regulated affiliates may use separate legal names across jurisdictions.
Corporate and disclosure information
| Organization | Redmile Group |
| Headquarters | San Francisco, United States |
| Public source | www.redmilegroup.com |
| Profile basis | Public institutional information and Capital Ranking editorial research |
Ranking recognition
Related Economy analysis
Selected Economy Markets articles provide context for the investment, market-structure, technology, financing and institutional themes relevant to this profile:
- Private Equity Technology Due Diligence in the AI Era
- How AI Is Reshaping Retail Due Diligence for Private Equity
- Technology Private Equity: Scale, Due Diligence and the Small-Cap Advantage
- Growth Equity vs Venture Capital and Buyouts: Key Differences
